1. Home
  2. TGTX vs LEA Comparison

TGTX vs LEA Comparison

Compare TGTX & LEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$55.33

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Logo Lear Corporation

LEA

Lear Corporation

HOLD

Current Price

$139.67

Market Cap

7.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGTX
LEA
Founded
1993
1917
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
7.2B
IPO Year
2008
1994

Fundamental Metrics

Financial Performance
Metric
TGTX
LEA
Price
$55.33
$139.67
Analyst Decision
Strong Buy
Buy
Analyst Count
5
14
Target Price
$49.80
$132.21
AVG Volume (30 Days)
2.5M
535.3K
Earning Date
05-04-2026
05-01-2026
Dividend Yield
N/A
2.49%
EPS Growth
1746.67
N/A
EPS
0.12
3.34
Revenue
$2,785,000.00
$23,259,100,000.00
Revenue This Year
$49.08
$2.50
Revenue Next Year
$26.69
$3.12
P/E Ratio
$459.33
$40.69
Revenue Growth
N/A
N/A
52 Week Low
$25.37
$91.67
52 Week High
$59.30
$150.33

Technical Indicators

Market Signals
Indicator
TGTX
LEA
Relative Strength Index (RSI) 60.43 55.96
Support Level $28.57 $139.14
Resistance Level $57.38 $141.92
Average True Range (ATR) 2.40 3.16
MACD -0.54 0.43
Stochastic Oscillator 51.47 90.20

Price Performance

Historical Comparison
TGTX
LEA

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

About LEA Lear Corporation

Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.

Share on Social Networks: